SYSTEM AND METHOD FOR IDENTIFYING AND COMMUNICATING WITH AN INTERVENTIONAL MEDICAL DEVICE von PAGE DOUGLAS A, GABRAIL PETER S, SUNNARBORG DANIEL N, WEDAN STEVEN R

Volltext bestellen

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias von Walker, Christopher J., Oaks, Joshua J., Santhanam, Ramasamy, Neviani, Paolo, Harb, Jason G., Ferenchak, Gregory, Ellis, Justin J., Landesman, Yosef, Eisfeld, Ann-Kathrin, Gabrail, Nash Y., Smith, Carrie L., Caligiuri, Michael A., Hokland, Peter, Roy, Denis Claude, Reid, Alistair, Milojkovic, Dragana, Goldman, John M., Apperley, Jane, Garzon, Ramiro, Marcucci, Guido, Shacham, Sharon, Kauffman, Michael G., Perrotti, Danilo

Volltext

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer von Chen, Ying, Camacho, Sandra Catalina, Silvers, Thomas R, Razak, Albiruni R A, Gabrail, Nashat Y, Gerecitano, John F, Kalir, Eva, Pereira, Elena, Evans, Brad R, Ramus, Susan J, Huang, Fei, Priedigkeit, Nolan, Rodriguez, Estefania, Donovan, Michael, Khan, Faisal, Kalir, Tamara, Sebra, Robert, Uzilov, Andrew, Chen, Rong, Sinha, Rileen, Halpert, Richard, Billaud, Jean-Noel, Shacham, Sharon, McCauley, Dilara, Landesman, Yosef, Rashal, Tami, Kauffman, Michael, Mirza, Mansoor R, Mau-Sørensen, Morten, Dottino, Peter, Martignetti, John A

Volltext

Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors von Chan, Emily, Chiorean, E. Gabriela, O’Dwyer, Peter J., Gabrail, Nashat Y., Alcindor, Thierry, Potvin, Diane, Chao, Richard, Hurwitz, Herbert

Volltext

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma von Vij, Ravi, Wang, Michael, Kaufman, Jonathan L., Lonial, Sagar, Jakubowiak, Andrzej J., Stewart, A. Keith, Kukreti, Vishal, Jagannath, Sundar, McDonagh, Kevin T., Alsina, Melissa, Bahlis, Nizar J., Reu, Frederic J., Gabrail, Nashat Y., Belch, Andrew, Matous, Jeffrey V., Lee, Peter, Rosen, Peter, Sebag, Michael, Vesole, David H., Kunkel, Lori A., Wear, Sandra M., Wong, Alvin F., Orlowski, Robert Z., Siegel, David S.

Volltext

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study von Garassino, Marina Chiara, Kim, Joo-Hang, Corral Jaime, Jesus, Powderly, John, Bidoli, Paolo, Wheatley-Price, Paul, Park, Keunchil, Wadsworth, Catherine, Dennis, Phillip A, Rizvi, Naiyer A, Paz-Ares Rodriguez, Luis, Novello, Silvia, Hiret, Sandrine, Schmid, Peter, Laack, Eckart, Califano, Raffaele, Vicente Baz, David, Berghmans, Thierry, Kim, Dong-Wan, Surmont, Veerle, Reck, Martin, Han, Ji-Youn, Holgado Martin, Esther, Chella, Antonio, Chopra, Akhil, Robinet, Gilles, Soto Parra, Hector, Thomas, Michael, Katakami, Nobuyuki, Su, Wu-Chou, Kim, Young-Chul, Lee, Jong-Seok, Saka, Hideo, Milella, Michele, Ramos Garcia, Inmaculada, Sibille, Anne, Atagi, Shinji, Spaeth-Schwalbe, Ernst, Nishio, Makoto, Imamura, Fumio, Derijcke, Sofie, Maeda, Tadashi, Zylla, Dylan, Santoro, Armando, Uy, Ma. Noemi, Lucien Geater, Sarayut, Kowalski, Dariusz, Chen, Yuh-Min, Spigel, David, Chewaskulyong, Busyamas, Garcia Gomez, Ramon, Alvarez Alvarez, Rosa, Yang, Chih-Hsin, Denis, Fabrice, Sakai, Hiroshi, Canon, Jean-Luc, Scholz, Christian, Kemmotsu, Hirotsugu, Azuma, Koichi, Feld, Ronald, Jassem, Jacek, Kubota, Kaoru, Waterhouse, David, Coudert, Bruno, Mark, Zsuzsanna, Chang, Gee-Chen, Herzmann, Christian, Chaudhry, Arvind, Giridharan, Selvaraj, Hesketh, Paul, Boccia, Ralph, Iannotti, Nichola, Haigentz, Missak, Reynolds, John, Nakagawa, Kazuhiko, Sugawara, Shunichi, Tan, Eng Huat, Takeda, Koji, Mohn-Staudner, Andrea, Panwalkar, Amit, Daniel, Davey, Kobayashi, Kunihiko, Ladrera, Guia Elena Imelda, Coupkova, Helena, Havel, Libor, Singh, Joginder, Murakami, Shuji, Anderson, Ian, Iqbal, Mussawar, Torri, Vamsee, Juhasz, Erzsebet, Koubkova, Leona, Levy, Benjamin, Page, Ray, Crinò, Lucio, Einspahr, David, Hagenstad, Christopher, Juat, Necy, Overton, Lindsay, Szalai, Zsuzsanna

Volltext

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy von Ryan, Charles J, Smith, Matthew R, de Bono, Johann S, Molina, Arturo, Logothetis, Christopher J, de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, Josep M, Ng, Siobhan, Carles, Joan, Mulders, Peter F.A, Basch, Ethan, Small, Eric J, Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D, Suttmann, Henrik, Gerritsen, Winald R, Flaig, Thomas W, George, Daniel J, Yu, Evan Y, Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S, Taplin, Mary-Ellen, Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I, Rathkopf, Dana E

Volltext

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, ph... von Richardson, Paul G, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Lindsay, Jindriska, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Schey, Steve, Yu, Xin, Bensmaine, Amine, Zaki, Mohamed, Abildgaard, Niels, Adler, Howard, Altuntas, Fevzi, Arce-Lara, Carlos, Aydin, Yildiz, Basu, Supratik, Battini, Ramakrishna, Beeker, Thaddeus, Ben-Yehuda, Dina, Boccia, Ralph, Cavo, Michele, Chantry, Andrew, Chaudhry, Arvind, Corso, Alessandro, De Arriba, Felipe, Delimpasi, Sosana, Desjardins, Pierre, Dhakal, Binod, Di Bartolomeo, Paolo, Dürig, Jan, Engelhardt, Monika, Esteves, Graca, Flogegard, Max, Gabrail, Nashat, Gamberi, Barbara, Garrison, Mitchell, Gisslinger, Heinz, Goldschmidt, Hartmut, Gressot, Laurent, Grosicki, Sebastian, Hanna, Wahid, Henriques Bernardo, Maria Manuela, Hermann, Robert, Holden, Viran, Huben, Marianne, Janakiram, Murali, Jenner, Matthew, João, Cristina, Jurcyszyn, Artur, Kalayoğlu Beşişik, Sevgi, Kambhampati, Suman, Karadoğan, Ihsan, Khojasteh, Ali, Kirkel, Dean, Komarnicki, Mieczyslaw, Lauri, Birgitta, Leleu, Xavier, Matsue, Kosei, Mendeleeva, Larisa, Miller, Carole, Mohrbacher, Ann, Müldür, Ercan, Naassan, Anthony, Nahi, Hareth, Nair, Rajesh, O'Dwyer, Mike, Openshaw, Thomas, O'Rourke, Timothy, Osswald, Michael, Overton, Lindsay, Pavic, Michel, Pierola, Ana Alfonso, Rabin, Neil, Ramasamy, Karthik, Rambaldi, Alessandro, Rodriguez, Paula, Röllig, Christoph, Rosenblatt, Jacalyn, Rosenbluth, Jonathan, Salomo, Morten, Samoylova, Olga, Sastre Moral, Jose, Shafeek, Salim, Shinagawa, Atsushi, Sleckman, Bethany, Smith, Clay, Suzuki, Kenshi, Takezako, Naoki, Teke, Hava Üsküdar, Vapaatalo, Mirja, Vassilopoulos, George, Verma, Amit, Wang, Xiang Sean, Yağci, Munci

Volltext

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study von Verstovsek, Srdan, Vannucchi, Alessandro M, Al-Ali, Haifa Kathrin, Lavie, David, Kuykendall, Andrew T, Grosicki, Sebastian, Lazaroiu, Mihaela C, McLornan, Donal, Yoon, Sung-Soo, Granacher, Nikki, Lee, Sung-Eun, Passamonti, Francesco, Klencke, Barbara J, Donahue, Rafe, Kawashima, Jun, Abulafia, Adi Shacham, Al-Ali, Haifa Kathrin, Andreasson, Bjorn, Ayala, Rosa, Bang, Soo-Mee, Bank, Bruce, Barraco, Fiorenza, Bonifacio, MassimiliaNo, Bories, Claire, Broliden, Andes, Buxhofer-Ausch, Veronika, Cambier, Nathalie, Caramella, Marianna, Cascavilla, Nicola, Castellano, Maria Giraldo, Chang, Hung, Choi, Yunsuk, Choi, Philip, Cuadrado, Isabel Montero, Cunningham, Julia, Damaj, Gandhi Laurent, De Stefano, Valerio, Diaz, Jose Miguel Torregrosa, Dombi, Péter, Dubruille, Viviane, Egyed, Miklós, El Fassi, Daniel, Elli, Elena Maria, Ellis, Martin, Fava, Carmen, Fazal, Salman, Fox, Laura, Garcĺa-Gutiérrez, Jose Valentĺn, Gluvacov, Alexandru, Goh, Yeow Tee, Granacher, Nikki, Grosicki, Sebastian, Gupta, Vikas, Hamed, Aryan, Hasselbalch, Hans, Hauser, Hanns, Heaney, Mark, Hebart, Holger, Hillis, Christopher, Hou, Hsin-An, How, Jonathan, Illés, Arpad, Isidori, Alessandro, Koren-Michowitz, Maya, Koschmieder, Steffen, Kosztolanyi, Szabolcs Ors, Kreiniz, Natalia, Laribi, Kamel, Lascaux, Axelle, Lavie, Noa, Lazaroiu, Mihaela, Leahy, Michael, Lee, Sung-Eun, Legrand, Ollivier, Macarie, Ioan, Marolleau, Jean-Pierre, Martelli, Maurizio, McCloskey, James, McDermott, Christopher, McMahon, Brandon, Mikala, Gábor, Mishchenko, Elena, Moon, Joon Ho, Nagy, Zsolt, Narayanan, Srinivasan, Oh, Stephen, Ojeda-Uribe, Mario, Ong, Kiat Hoe, Passamonti, Francesco, Patriarca, Andrea, Prejzner, Witold, Rachow, Tobias, Rinaldi, Ciro, Robak, Tadeusz, Sadjadian, Parvis, Scheid, Christof, van Droogenbroeck, Janusz, Vianelli, Nicola, Xicoy, Blanca, Yeh, Su-Peng

Volltext

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma von Kuruvilla, John, Savona, Michael, Baz, Rachid, Mau-Sorensen, Paul Morten, Gabrail, Nashat, Garzon, Ramiro, Stone, Richard, Wang, Michael, Savoie, Lynn, Martin, Peter, Flinn, Ian, Jacoby, Meagan, Unger, Thaddeus J., Saint-Martin, Jean-Richard, Rashal, Tami, Friedlander, Sharon, Carlson, Robert, Kauffman, Michael, Shacham, Sharon, Gutierrez, Martin

Volltext

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) von Chen, Christine, Garzon, Ramiro, Gutierrez, Martin, Jacoby, Meagan A., Brown, Peter, Flinn, Ian, Stone, Richard M., Savoie, Mary Lynn, Baz, Rachid, Gabrail, Nashat Y., Wang, Michael, Martin, Peter, Siegel, David, Mau-Sørensen, Morten, Andreef, Michael, Marshall, Tracey, Saint-Martin, Jean-Richard, Carlson, Robert, Shacham, Sharon, Kauffman, Michael, Kuruvilla, John

Volltext

TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements von Doebele, Robert Charles, Lin, Jessica Jiyeong, Nagasaka, Misako, Zhu, Viola Weijia, Gabrail, Nashat Y., Bazhenova, Lyudmila, Anderson, Peter Meade, Solomon, Benjamin J., Dudek, Arkadiusz Z., Pippas, Andrew William, Shirinian, Mihran, Baik, Christina S, Stopatschinskaja, Shanna, Camidge, D. Ross, Cho, Byoung Chul, Drilon, Alexander E.

Volltext

A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC) von Sonpavde, Guru, Maughan, Benjamin Louis, Wei, Xiao X., McGregor, Bradley Alexander, Kilbridge, Kerry L., Lee, Richard J., Yu, Evan, Schweizer, Michael Thomas, Montgomery, Robert B., Cheng, Heather H., Hsieh, Andrew Caleb, Birhiray, Ruemu E., Gabrail, Nashat Y., Nemunaitis, John J., Rezazadeh, Arash, Van Veldhuizen, Peter J., Vogelzang, Nicholas J., Heery, Christopher Ryan, Grivas, Petros

Volltext

Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1 von Garon, Edward B., Schneider, Jeffrey Gary, Wong, Deborah J.L., Aljumaily, Raid, Korn, Wolfgang Michael, Infante, Jeffrey R., Patel, Manish R., Autio, Karen A., Papadopoulos, Kyriakos P., Naing, Aung, Gabrail, Nashat Y., Munster, Pamela N., Goldman, Jonathan Wade, Hung, Annie, Van Vlasselaer, Peter, Leveque, Joseph, Oft, Martin, Spigel, David R.

Volltext

A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung von Leighl, Natasha B., Raez, Luis E., Besse, Benjamin, Rosen, Peter J., Barlesi, Fabrice, Massarelli, E., Gabrail, Nashat, Hart, Lowell L., Albain, Kathy S., Berkowitz, Lloyd, Melnyk, Ostap, Shepherd, Frances A., Sternas, Lars, Ackerman, Judie, Shun, Zhenming, Miller, Vincent A., Herbst, Roy S.

Volltext

Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC von Wong, Deborah Jean Lee, Schneider, Jeffrey Gary, Aljumaily, Raid, Korn, Wolfgang Michael, Infante, Jeffrey R., Patel, Manish R., Autio, Karen A., Papadopoulos, Kyriakos P., Naing, Aung, Gabrail, Nashat Y., Munster, Pamela N., Goldman, Jonathan Wade, Van Vlasselaer, Peter, Brown, Gail Linda, Hung, Annie, Oft, Martin, Garon, Edward B.

Volltext

Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label... von Hari, Parameswaran N., Shain, Kenneth H., Voorhees, Peter M., Gabrail, Nashat, Abidi, Muneer H., Zonder, Jeffrey, Boccia, Ralph V., Richardson, Paul G., Neuman, Linda L., Dixon, Sandra J., Paba Prada, Claudia

Volltext

Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-re... von Martignetti, John, Razak, Albiruni R.A., Chen, Ying, Gabrail, Nashat Y., Gerecitano, John F., Camacho, Catalina, Pereira, Elena, Dottino, Peter Remsen, Shacham, Sharon, McCauley, Dilara, Rashal, Tami, Saint-Martin, Jean-Richard, Shacham, Eran, Vincett, Darcy, Kauffman, Michael, Mirza, Mansoor Raza, Sorensen, Morten

Volltext

A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL) von Gutierrez, Martin, Goy, Andre, Byrd, John C., Flynn, Joseph M., Sorensen, Morten, Brown, Peter, Gabrail, Nashat Y., Savona, Michael, Flinn, Ian, Baz, Rachid C., Shah, Bijal D., Stone, Richard M., Jacobsen, Eric, Kukreti, Vishal, Tiedemann, Roger E., Rashal, Tami, Mirza, Mansoor Raza, Shacham, Sharon, Kauffman, Michael, Kuruvilla, John

Volltext

A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with relapsed/refractory acute myeloid leukemia (AML) von Yee, Karen W. L., Savona, Michael, Sorensen, Morten, Brown, Peter, Blum, William G., DeAngelo, Daniel J., Gutierrez, Martin, Garzon, Ramiro, Schuh, Andre C., Gabrail, Nashat Y., Wadleigh, Martha, Lancet, Jeffrey E., Shah, Bijal D., Berdeja, Jesus G., Wagner-Johnston, Nina D., Flinn, Ian, Rashal, Tami, Kauffman, Michael, Shacham, Sharon, Stone, Richard M.

Volltext